BACKGROUND Recently, many broadly applicable and potent neutralizing antibodies have been screened from HIV-1-infected patients. However, all these effective neutralizing antibodies were isolated from patients naive to anti-retroviral treatment (ART).… Click to show full abstract
BACKGROUND Recently, many broadly applicable and potent neutralizing antibodies have been screened from HIV-1-infected patients. However, all these effective neutralizing antibodies were isolated from patients naive to anti-retroviral treatment (ART). METHODS To better understand the induction of neutralizing antibodies in patients on ART, we screened 3 patients with an over ten-year infection history on ART from 350 patients in China for a cross-reactive neutralizing antibody response based on the use of different antigens and recombinant viruses. We studied the evolution of neutralizing activity in two patients during a one-year period with previously described recombinant viruses NL4-3 and SF162 using ELISA and neutralization assays. RESULTS Antibodies purified from sera were able to react with recombinant virus antigens R2-gp120 and SF162-gp140 and neutralize SF162 recombinant virus but not NL4-3 recombinant virus. In addition, we observed a significant increase in the neutralizing response of immunoglobulin G (IgG) isolated from the serum sample in Patient 1 and compared it with the serum from Patient 1 six months ago. CONCLUSIONS We thus confirm the possibility of production of neutralizing antibodies in patients infected for over ten years on ART, and it is possible over time of the improvement of HIV-1 potent neutralizing activity associated with viremia and immune reconstruction.
               
Click one of the above tabs to view related content.